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vs APB DC including surface molecules HLA-DQA1 (4F), HLA-
DRB3 (5F); cytokine/chemokine genes IL6 (2.9F), IL12B (3.5F),
CXCL10 (6.6F); immunoregulatory genes ISG20 (11F),
TNFSF10 (4.5F). The proteomic results indicated several zinc
ﬁnger proteins (292, 221) (2-5F) and interleukin-4 precursor (7.7F)
were expressed higher in APB vs CB (mDC). In contrast, cell cycle
regulators cyclin I (3F), Rb-like protein 2 (4.35 F) were signiﬁ-
cantly lower in APB vs CB DC. We then compared CB vs APB DC
antigen presentation activity to APB CD8 T cells by ELISPOT
assay for interferon-r (IFNr) production (BD Pharmingen).
Brieﬂy, CD8 T cells (MHC HLA A2) were incubated with CB or
APB DC that were loaded without or with inﬂuenza peptide onto
ELISPOT plate. Inﬂuenza peptide loaded CB mDC signiﬁcantly
reduced the ability to induce CD8 T cells to produce IFNr com-
pared with APB mDC (3.5F). We postulate that decreased expres-
sion of speciﬁc surface molecules and other genes and proteins
resulting in lower surface protein expression in CB DC may in part
be responsible for the lack of initiation of cell surface signaling
events to trigger CB-DC to induce activation of CD8 T cells.
Furthermore, these signiﬁcantly decreased expressed genes and
proteins in LPS-CB vs APB DC may also partially be responsible
for differential innate and adaptive immune function and proper-
ties of CB vs. APB.
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EX VIVO ACTIVATED AND TRANSDUCED HUMAN T CELLS GENERATE
LETHAL GVHD IN A MOUSE MODEL, AND ARE EFFICIENTLY ELIMI-
NATED IN VIVO WITH SUICIDE GENE THERAPY
Nervi, B.1, Rettig, M.P.1, Ritchey, J.K.1, Wang, H.L.1, Bauer, G.1,
Walker, J.1, Bonyhadi, M.L.2, Berenson, R.J.2, Herrbrich, P.E.1,
Hess, D.1, Nolta, J.A.1, DiPersio, J.F.1 1. Washington University
School of Medicine, St. Louis, MO; 2. Xcyte Therapies, Inc., Seattle,
WA.
No in vivo models exist to consistently examine the impact of
ex vivo manipulation of human T cells (huT) on T cell function.
NOD SCID2Mnull mice (2) were conditioned with 250 cGy
TBI on day 1 (n  34), or 300 cGy on day 0 (n  21). 107 naive
or CD3/28 bead activated (Xcyte™ Dynabeads) huT (Act)
were injected retro-orbitally (ro). Engraftment of huT was eval-
uated weekly by FACS and euthanasia was performed if mice
lost 	20% body weight. 2 mice receiving 250 or 300 cGy 
naive, or 300 cGy  Act developed 60%, 75%, and 100% lethal
GVHD respectively. The huT engraftment was 20  15%, 33 
21%, and 59  19% respectively. Inﬁltration of murine tissues
was greatest in mice receiving 300 cGy  Act huT (spleen, liver,
lung, kidney: 60%). Of interest, serum human IFN levels
increased over time in all mice who developed lethal GVHD
(P  .05). Importantly, histological examination of the target
tissues revealed changes consistent with human GVHD. We
developed a chimeric suicide gene consisting of human CD34
and full length HSV-tk and showed that the fusion protein
CD34-TK conferred ganciclovir (GCV) sensitivity and pro-
vided a surface marker for selection of transduced cells (Td). To
generate Td cells we used CD3/28 beads  IL-2, and after 2
days cells were incubated with 293 GPG-derived VSV-G
pseudotyped CD34-tk oncoretroviral supernatants for 6h at
37C. Td cells were then expanded for 2 more days and isolated
by MACS (Miltenyi Biotech) and puriﬁed to 	99% by CD34
(VarioMACS). To evaluate the Td GVHD potential, 2 mice
received 300 cGy and were injected with 107 Act (n  7) or Td
(n  4) huT. Both groups developed similar engraftment with
49  23% and 49  10% huT respectively (P  NS); had
important inﬁltration in target organs (55% in the liver), and
developed lethal GVHD. Subsequently, we evaluated the ability
of GCV (days 1-7) to prevent GVHD after infusion of Td. 2
mice (n  8) conditioned with 300 cGy were injected ro with
107 Td and 50% received GCV. We efﬁciently eliminated Td
huT with GCV (day 3 0.1  0.06; day 24 0.1  0.1 Td cells). In
summary, we developed a xenogeneic model of lethal GVHD
where naive, ex vivo activated, or Td selected CD34tk huT
injected ro into sublethally irradiated 2 mice engraft, expand in
vivo, inﬁltrate target tissues sharing the major characteristics of
human GvHD, and causing the death of mice. Interestingly, Td
T cells could be efﬁciently eliminated in vivo by treatment with
GCV, meaning we could potentially control human GVHD
with the suicide system.
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PERSISTENT MIXED CHIMERISM IN PLASMA CELLS FOLLOWING AL-
LOGENEIC STEM-CELL TRANSPLANTATION (SCT) IN PATIENTS WITH
ACUTE LEUKEMIA IS A SURROGATE MARKER FOR LEUKEMIA RELAPSE
Shimoni, A., Trakhtenbrot, L., Ishoev, G., Hardan, I., Shem-Tov, N.,
Rechavi, G., Amariglio, N., Nagler, A. Chaim Sheba Medical Center,
Tel-Hashomer, Israel.
Chimerism within cellular subsets following allogeneic SCT has
been studied extensively, yet there is only limited data on chimer-
ism kinetics within plasma cells (PC) and its prognostic signiﬁ-
cance. In this study we prospectively analyzed the relative ratios of
recipient and donor-derived PC in pts with acute leukemia at serial
time-points following SCT from a sex-mismatched donor in rela-
tion to SCT outcomes. Bone-marrow (BM) preparations were
evaluated by a Duet combined cytogenetic/morphologic analysis
system (Bioview LtD, Israel). The system scans BM preparations
and saves all cell coordinates. PC are detected and marked by their
morphology. The stain is then removed and FISH for  and Y
markers is applied to the same slide allowing differentiation of
recipient and donor PC by their gender. The study included 50 pts
following myeloablative (n  22) or reduced-intensity condition-
ing (n  28). Thirty-six pts (72%) had recipient PC detected early
after SCT, constituting 0.01-1.6% of BM cells. This was often
associated with low level recipient chimerism (1%) in lympho-
cytes. Early detection of recipient PC was not related to donor
type, conditioning regimen or acute GVHD, and had no prognos-
tic signiﬁcance. The median time to disappearance of recipient PC
was 12 months. In 16 of the 36 pts with recipient PC they persisted
beyond 6 months (and up to 	18 months), in 10 they disappeared
by this time period, 6 died before 6 months with recipient PC and
4 have insufﬁcient follow-up. Persistence of recipient PC beyond 6
months was not associated with mixed-chimerism in other subsets
at this stage. BM tests beyond 6 months are available in 30 pts of
all 50 pts. The outcome of 16 pts with recipient PC persisting
beyond 6 months was signiﬁcantly inferior to 14 pts with no
recipient PC at this stage; 8 patients in the ﬁrst group relapsed
compared to only 1 pt in the second. The 2-year DFS was 35%
(7-62), and 91% (74-100), respectively (P  .02). Donor derived
PC were detected during the course in 27 pts. The estimated
median time to ﬁrst detection of donor PC was 6 months (1-15).
Engraftment kinetics of donor PC had no relation to SCT out-
comes. In conclusion, recipient PC may persist for long durations
after allogeneic SCT and are relatively resistant to conditioning
and to allogeneic responses. Persistence of recipient PC beyond 6
months is a surrogate marker for ineffective GVL, even in pts with
GVHD, and is therefore associated with an increased risk for
leukemia relapse.
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INTENTIONAL INDUCTION OF IMMUNE-HEMATOPOIETIC MIXED CHI-
MERISM AS A PLATFORM FOR EARLY CELLULAR THERAPY IN PEDIAT-
RIC LEUKEMIA PATIENTS AFTER ALLOGENEIC TRANSPLANTATION:
ENHANCING GVL EFFECT WHILE AVOIDING GVHD
Diaz, M.A., Ramirez, M., Perez-Martinez, A., Gonzalez-Vicent, M.,
Garcia-Castro, J., Madero, L. Hematopoietic Stem Cell Transplantation
Unit, Hospital “Nin˜o Jesus,” Madrid, Spain.
To maximize graft-versus-leukemia (GvL) effect while mini-
mizing transplant-related morbidity and mortality, we designed
a study of allogeneic PBSC CD34 selected transplantation
followed by DLI. PBSC CD34 selection was performed by
CliniMACS device. Between June 2004 and July 2005, sixteen
consecutive patients (4 females and 12 males) aged between 1-12
years (median 6 years) diagnosed with AML 6, ALL 10 were
conditioned with ﬂudarabine 30 mg/m2/day  4 days and mel-
phalan 140 mg/m2/day  1 day. Status at transplantation was 1st
CR 10, 2nd CR 5 and 3rd CR 1. GvHD prophylaxis consisted of
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CsA  short Mtx. Patients were grafted with a median number
of 7  106/kg CD34 cells (range: 1.5-31  106/kg) and 1.7 
104 CD3 cells (range: 0.4-5.9  104/kg). All patients engrafted
and achieved mixed chimerism. Median time to neutrophil and
platelet engraftment was 12 days (range: 9-15 days) and 12 days
(range: 8-24 days), respectively. DLI of 0.5  105/kg CD3
cells were scheduled on day 15, 30 and 60. A total of 46
DLI were performed. The median follow-up for survivors is 6
months (range: 3-16 months). No patient developed acute
GvHD grade 2 or higher and one developed chronic GvHD.
One patient died on day 12 due to engraftment syndrome.
The probability of TRM was 6% (95% CI; 2%-10%). Another
patient died of relapsed disease on day 70. The probability of
relapse was 7% (95% CI; 2%-12%).The DFS is 87% (95% CI;
78%- 96%).The preliminary results of our transplantation strat-
egy are encouraging. A large prospective study is needed to
substantiate these results.
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EARLY DONOR LYMPHOCYTE INFUSION (DLI) DOES NOT CONSIS-
TENTLY PREVENT GRAFT REJECTION IN DOGS GIVEN DLA-IDENTICAL
MARROWS AFTER 1 Gy TOTAL BODY IRRADIATION (TBI)
Baron, F., Sandmaier, B., Zellmer, E., Sorror, M., Little, M.T.,
Storb, R. Fred Hutchinson Cancer Research Center, Seattle, WA.
Background: Secondary graft rejections may occur after non-
myeloablative conditioning for hematopoietic cell transplanta-
tion (HCT), particularly in patients with chronic myeloid leu-
kemia given unrelated grafts (Biol Blood Marrow Transplant.
2005;11:272). We have shown that low (50%) donor T-cell
and NK cell chimerism levels on day 14 after HCT predicted
graft rejection (Blood. 2004;104:2254). Here we investigated in a
pre-clinical canine model of HCT, whether pre-emptive DLI
given 1 month after HCT could prevent secondary graft rejec-
tion that was the rule in dogs given DLA-identical marrow after
suboptimal conditioning with 1 Gy TBI and postgrafting im-
munosuppression with cyclosporine (CSP) combined with ei-
ther mycophenolate mofetil (MMF) or rapamycin (11 of 11 dogs
experienced graft rejection by wk 12). Methods: 9 dogs were
given DLA-identical marrow grafts after 1 Gy TBI followed by
postgrafting immunosuppression with MMF (days 0-27) and
CSP (started on day 1 and discontinued 1 day before DLI). A
single DLI (containing 1.0-2.3  108 T-cells/kg) was given
28-36 days after HCT in each dogs. In addition, 5 of 9 dogs
received pentostatin, 4 mg/m2 given 2 days before DLI (n  3);
or 4 mg/m2/day on days 4-2 before DLI (n  2) (Table 1).
Presence of donor cells in peripheral blood mononuclear cells
(PBMC) was assessed by VNTR-PCR. The endpoint of the
study was persistence of mixed donor/host chimerism at 30 wks.
Results: Marrow cell numbers were similar in DLI and histor-
ical dogs (medians 3.6  108and 4.0  108 nucleated cells/kg,
respectively, P  .20). Two of the ﬁrst 4 dogs given DLI only
were mixed donor-host chimeras at 30 wks, while 2 rejected
their grafts on wks 10 and 15, respectively. We then investigated
in 5 dogs whether host immunosuppression with pentostatin
prior to DLI could overcome the pending rejection and increase
the efﬁcacy of DLI. Three of the 5 dogs (including 1 of the 2
given 3 doses of pentostatin) rejected their grafts on wks 8, 12
and 16 after HCT, respectively, while 1 was a stable mixed
donor/host chimera 24 wks after HCT, and 1 was too early to be
evaluated. The 30-wk probability of sustained donor engraft-
ment was 37.5% in dogs given DLI, versus 0% in historical dogs
(P  .01). Conclusions: DLI, with or without preceding pen-
tostatin, was effective in one third of dogs studied to prevent
graft rejection. The model might be useful to develop further
strategies aimed at preventing graft rejection in patients with








(Final % of Donor
Chimerism in PBMC)
1 No 40 >30 (54)
2 No 13.1 10 (0)
3 No 7.7 15 (0)
4 No 12.4 >30 (5)
5 4 mg/m2 23.1 16 (0)
6 4 mg/m2 20.5* 12 (0)
7 4 mg/m2 16.2 >24 (14.4)
8 3  4 mg/m2 9.9 8 (0)
9 3  4 mg/m2 Too early Too early
*4 days after DLI.
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EX VIVO EXPANDED T REGULATORY (TREG) CELLS BLOCK THE BREAK-
ING OF TOLERANCE IN MIXED CHIMERAS
Lesnikova, M.1, Nikitine, A.1, Mason, N.2, Storb, R.F.1,3,
Nash, R.A.1,3, Georges, G.E.1,3 1. Fred Hutchinson Cancer Research
Center, Seattle, WA; 2. University of Pennsylvania, Philadelphia, PA;
3. University of Washington, Seattle, WA.
Nonmyeloablative allogeneic hematopoietic cell transplantation
(HCT) consisting of 2 Gray (Gy) total body irradiation (TBI), dog
leukocyte antigen-identical marrow, and short-term postgrafting im-
munosuppression with cyclosporine and mycophenolate mofetil was
developed in the dog model as an effective way to establish long-term,
stable mixed hematopoietic chimerism. We hypothesized that Treg
cells are crucial to maintaining stable mixed chimerism. All dogs in the
current study were stable mixed chimeras established as described.
Previously, we showed in 8 mixed chimeras that naive DLI did not
change the percent donor chimerism. We asked if reconditioning
mixed chimeras with a nonmyeloablative dose of 2 Gy TBI followed
by DLI could increase donor chimerism. Seven mixed chimeras were
re-conditioned with 2 Gy TBI followed by DLI (median dose, 1.5 
108CD3/kg). Within 4 weeks after DLI, conversion to 100% donor
chimerism was seen in 5 of 7 dogs and 2 dogs had a 	50% sustained
increase in donor chimerism. A control group of 3 mixed chimeras
reconditioned with 2 Gy TBI without DLI had no change in donor
chimerism. These results show that reconditioning with 2 Gy TBI
followed by DLI can break the tolerance mechanism established in
mixed chimeras. Next, we asked if CD4CD25 Treg cells obtained
from mixed chimeras prior to reconditioning could block the increase
in donor chimerism following 2 Gy TBI and DLI. Peripheral blood
mononuclear cells (PBMC) were obtained from mixed chimeras by
leukapheresis and were activated with 3rd party irradiated PBMC and
CD34 derived dendritic cells. On day 4 of culture, CD25 cells were
isolated by immunomagnetic selection. Artiﬁcial antigen presenting
cells (aAPC) were added to expand the CD4CD25 Treg cells. The
aAPC expressed CD32, CD86, and IL-15, and were loaded with
mitogenic anti-CD3 antibody. After 10 days, CD4CD25 Treg
cells had expanded a median of 23-fold and inhibited MLR. To date,
Treg were generated from 4 mixed chimeric dogs and were infused
back into the respective mixed chimera (median cell dose, 1.0 
107/kg) after reconditioning with 2 Gy TBI and immediately prior to
DLI. In 3 of 4 dogs, there was no signiﬁcant change in donor
chimerism after 12-16 weeks and 1 dog converted to complete donor
chimerism within 6 weeks. These preliminary results suggest that ex
vivo expanded CD4CD25 Treg cells have in vivo function and can
restore the tolerance mechanism in mixed chimeras that is broken by
2 Gy TBI and DLI.
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